Source link : https://www.newshealth.biz/health-news/tyk2-inhibitor-shows-early-promise-in-psoriatic-arthritis/
TOPLINE: The tyrosine kinase 2 (TYK2) inhibitor TAK-279 demonstrated superiority to placebo in patients with active psoriatic arthritis (PsA), according to phase 2 trial results. METHODOLOGY: Eligible patients were over 18 years old, had PsA for over 6 months, met the classification criteria for PsA, and had at least three swollen and tender joints despite […]
Author : News Health
Publish date : 2024-06-25 09:13:44
Copyright for syndicated content belongs to the linked Source.
Categories